A recent review of the research from the National Academies of Sciences, Engineering, and Medicine attempts to fill the gap in our knowledge. By combing through more than 10,000 studies published since 1999, the review, conducted by more than a dozen experts, provides the clearest look at the scientific evidence on marijuana yet.
With the problems specifically linked to smoking marijuana, it’s worth noting that other forms of consumption — vaping and edibles in particular — may not carry the same risk. More research will be needed to evaluate that, particularly for vaping.
Share this story
The report also disproved — or at least cast a lot of doubt — on some of the claimed benefits of pot. It found “limited evidence” that marijuana is ineffective for treating symptoms associated with dementia and glaucoma, as well as depressive symptoms in individuals with chronic pain or multiple sclerosis.
Overall, the report suggests that, as far as therapeutic benefits go, marijuana is a solid treatment for multiple symptoms associated to chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis. Everything else, from epilepsy to HIV/AIDS, needs more research before pot is more definitively shown to be effective or ineffective.
A new report looks at more than 10,000 studies on marijuana. It has good and bad news for pot users.
The marijuana industry is made up of companies that either support or are engaged in the research, development, distribution, and sale of medical and recreational marijuana. Cannabis has begun to gain wider acceptance and has been legalized in a growing number of nations, states, and other jurisdictions for recreational, medicinal, and other uses. Some of the biggest companies in the marijuana industry include Canopy Growth Corp. (CGC), Cronos Group Inc. (CRON), and Tilray Inc. (TLRY). Many big marijuana companies have continued to post sizable net losses as they focus on investing in equipment to speed up revenue growth.
Momentum investing is a factor-based investing strategy in which you invest in a stock whose price has risen faster than the market as a whole. Momentum investors believe that stocks which have outperformed the market will often continue to do so, because the factors that caused them to outperform will not suddenly disappear. In addition, other investors, seeking to benefit from the stock’s outperformance, will often purchase the stock, further bidding its price higher and pushing the stock higher still. These are the stocks that had the highest total return over the last 12 months.
HITI.V is top for value and JUSH.CX is top for growth and momentum
Here are the top 5 marijuana stocks with the best value, the fastest growth, and the most momentum.
These are the marijuana stocks with the lowest 12-month trailing price-to-sales (P/S) ratio. For companies in the early stages of development or industries suffering from major shocks, this can be substituted as a rough measure of a business’s value. A business with higher sales could eventually produce more profit when it achieves, or returns to, profitability. The P/S ratio shows how much you’re paying for the stock for each dollar of sales generated.
Marijuana stocks, as represented by the ETFMG Alternative Harvest ETF (MJ), have slightly outperformed the broader market. MJ has provided a total return of 36.9% over the past 12 months, above the Russell 1000 index’s total return of 35.0%. These market performance numbers and all statistics in the tables below are as of Aug. 23, 2021.
Overly “wet” buds have stems that don’t snap and tend to stay put when squeezed. The extra moisture content makes for the perfect breeding ground for mold and mildew. Wet nugs that tear apart rather than break apart are a sign that a cultivator didn’t properly dry and cure their cannabis.
Identifying high-quality flower can throw even the most experienced cannabis connoisseurs for a loop, but the key traits that separate good weed from bad weed are smell, appearance, feel, and flower structure. In this article, we’ll break down all four and offer tips for spotting the good stuff and avoiding the bad.
4. Flower structure: Skillfully cultivated and cured sativa-leaning flowers tend to be light and fluffy in shape and composition, while indicas tend to be tighter and denser in flower structure. Though the structure and the experience you end up having usually have little to do with each other. Rock-hard flowers are a sign that cultivators may have used plant growth regulators, which can lead to an unpleasant taste. Extremely fluffy flowers could be a signal that the plant was not grown under sufficient light intensity and was not cultivated to its potential.
The best smoking experiences, edibles, tinctures — even CBD oil — often come from the best source material, or “top-shelf bud.” In terms of slang, premium weed is also commonly referred to as the “loud,” “fire,” “dank,” and “Private Reserve.” Low-grade weed is often referred to as “schwag,” “brick,” “ditch,” and “bunk” weed.
You may think you’re getting better quality bud with a sky-high THC concentration, but Dr. Rae dispels this myth. She cited THC levels above 20% as a red flag and told Weedmaps, “Lab tests are not as accurate as they may seem, and there are financial incentives for labs to produce increasingly higher THC values. Especially with flowers labeled around 30%, be very wary of fraudulent lab results.”
3. Feel: When flower is of a lower quality, it will often be dry or brittle to the touch. Dry bud will feel light and airy with no weight behind it, unlike dense, sticky flower. Additionally, bad weed will easily crumble when handled, or might even be falling apart. Loose, undone flower is called “shake” and should be avoided.
First, let’s cover our bases and go over the common terms used when shopping for good weed. “Flower” refers to the dried and cured female cannabis plant’s blooms, often called “nugs” or “buds.” Flower is typically intoxicating — THC content is the primary indicator of euphoric potency — but some flower has high CBD content and will produce less intoxicating effects.